Bath & Body Works (NYSE:BBWI) Issues FY25 Earnings Guidance

Bath & Body Works (NYSE:BBWI) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $3.06-3.26 for the period, compared to the consensus earnings per share estimate of $3.19. The company issued revenue guidance of down 2-4% yr/yr to ~$7.13-7.28 billion, compared to the consensus revenue estimate of $7.25 billion. Bath & Body Works also updated its Q3 guidance to $0.41-0.47 EPS.

Bath & Body Works Price Performance

BBWI stock opened at $30.52 on Thursday. The company’s 50 day simple moving average is $32.10 and its 200-day simple moving average is $40.46. The firm has a market capitalization of $6.69 billion, a PE ratio of 7.87, a P/E/G ratio of 0.96 and a beta of 1.77. Bath & Body Works has a 12 month low of $26.20 and a 12 month high of $52.99.

Bath & Body Works (NYSE:BBWI) last announced its earnings results on Wednesday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.02. Bath & Body Works had a net margin of 12.69% and a negative return on equity of 41.94%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.54 billion. As a group, sell-side analysts anticipate that Bath & Body Works will post 3.18 earnings per share for the current year.

Bath & Body Works Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 6th. Shareholders of record on Friday, August 23rd were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend was Friday, August 23rd. Bath & Body Works’s dividend payout ratio is currently 20.62%.

Analyst Ratings Changes

A number of research firms have commented on BBWI. Telsey Advisory Group restated an outperform rating and set a $53.00 price target on shares of Bath & Body Works in a research report on Wednesday, August 28th. Barclays cut their price objective on shares of Bath & Body Works from $32.00 to $31.00 and set an equal weight rating for the company in a research report on Thursday, August 29th. Morgan Stanley decreased their target price on shares of Bath & Body Works from $56.00 to $51.00 and set an overweight rating for the company in a research report on Thursday, September 5th. Bank of America cut their price target on Bath & Body Works from $54.00 to $45.00 and set a buy rating on the stock in a report on Thursday, August 29th. Finally, BMO Capital Markets restated an outperform rating and set a $50.00 price objective (down from $52.00) on shares of Bath & Body Works in a research note on Thursday, August 29th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Bath & Body Works has an average rating of Moderate Buy and an average target price of $43.00.

Bath & Body Works Company Profile

Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.